At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- FOLFIRI Regimen (drug), Sotorasib (drug), Panitumumab (drug), Bevacizumab-awwb (drug)
- How long the study runs
- Study runs about 93 months (dates as stated)
- About the drug or intervention
- FOLFIRI Regimen — drug: Combination of irinotecan, leucovorin, and 5-fluorouracil given via IV infusion Q2W. · Sotorasib — drug: Immediate-release solid dosage form administered orally. · Panitumumab — drug: Administered via IV infusion Q2W. · Bevacizumab-awwb — drug: Administered via IV infusion Q2W.
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 450
- Started
- 2024-07-17
- Last checked
- 2026-09
Plain English Summary
What is this study?
- • Testing a new treatment for metastatic colorectal cancer
- • Phase3 - 450 participants
- • The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with metastatic colorectal cancer
Where?
- • Birmingham - Queen Elizabeth Hospital Birmingham
- • Glasgow - Beatson West of Scotland Cancer Centre
- • London - Royal Free Hospital
- • London - Guys Hospital
- • +6 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
Biomarkers mentioned
What the study is looking for
- ✓Pathologically documented that has spread colorectal adenocarcinoma with KRAS p.G12C mutation by a locally validated assay.
- ✓Central laboratory detection of KRAS p.G12C mutation.
- ✓Measurable that has spread disease per (standard scan measurements) criteria.
- ✓activity scale (ECOG) Performance Status of ≤ 1.
- ✓healthy organ.
Who cannot take part
- ✗Active, untreated brain metastases.
- ✗Leptomeningeal disease
- ✗Previous treatment with a KRAS p.G12C inhibitor
- ✗History of interstitial pneumonitis or lung fibrosis or evidence of interstitial pneumonitis or lung...
See the full criteria
Where Is This Study? (10 UK sites)
Queen Elizabeth Hospital Birmingham
Birmingham B15 2TH, United Kingdom
Beatson West of Scotland Cancer Centre
Glasgow G12 0YN, United Kingdom
Royal Free Hospital
London NW3 2QG, United Kingdom
Guys Hospital
London SE1 9RT, United Kingdom
Royal Marsden Hospital
London SW3 6JJ, United Kingdom
Sarah Cannon Research Institute UK
London W1G 6AD, United Kingdom
Maidstone Hospital
Maidstone ME16 9QQ, United Kingdom
Denise Day / Julie Knowles
mtw-tr.researchgovernance@nhs.net01622 225627Mount Vernon Cancer Centre
Northwood HA6 2RN, United Kingdom
Weston Park Hospital
Sheffield S10 2SJ, United Kingdom
Royal Marsden Hospital - Sutton
Sutton SM2 5PT, United Kingdom
How to Get in Touch
Amgen Call Center
Sponsor contactCONTACT